Medicare Opens $50-a-Month GLP-1 Obesity Drug Pilot for 29 Million Starting in July
Updated
Updated · The New York Times · May 15
Medicare Opens $50-a-Month GLP-1 Obesity Drug Pilot for 29 Million Starting in July
8 articles · Updated · The New York Times · May 15
$50 a month will buy Medicare beneficiaries access to GLP-1 obesity drugs starting in July under a pilot that opens coverage previously barred for obesity alone.
29 million beneficiaries could qualify under the broader rules, including people with severe obesity and those with obesity plus prediabetes or uncontrolled hypertension; 16 million already had access through diabetes, cardiovascular disease or sleep apnea coverage.
40% of Medicare's 70 million enrollees meet the clinical definition of obesity, but even the new price adds about $600 a year for seniors already facing rising medical costs.
2027 is the pilot's current horizon, and making the benefit permanent would require a change in federal law and insurer agreement to include the drugs in Part D plans.
This new $50 obesity drug benefit for seniors is temporary. What is the plan for patients after 2027?
Beyond the advertised $50 price, what are the hidden costs for seniors in this new obesity drug program?
Medicare’s GLP-1 Bridge Program: Expanding Access to Weight-Loss Medications with a Flat $50 Copay (2026–2027)
Overview
The Medicare GLP-1 Bridge Program, launching July 1, 2026, is a temporary, nationwide initiative designed to expand access to weight-loss medications for eligible Medicare Part D beneficiaries. Running through December 31, 2027, it serves as a short-term demonstration project while the longer-term BALANCE Model faces delays. By providing a transitional solution, the program ensures broad access across all U.S. states and territories. Its main goal is to bridge the gap in obesity care, offering vital medications and setting the stage for future, more permanent Medicare coverage decisions.